Lebanon, NH – April 30, 2026 – Bio X Cell, the global leader in functional, in vivo-ready antibody solutions, today announced a strategic distribution partnership with Realgen-bio Co., Ltd., expanding access to ultrapure, low-endotoxin functional antibodies across Jiangsu and Anhui Provinces in China.
Founded in 2011 and headquartered in Suzhou, Realgen-bio Co., Ltd. has established itself as a trusted scientific partner to more than 4,000 organizations, including leading biopharmaceutical companies, cell therapy innovators, and government research institutions. With branch offices across China and a portfolio representing nearly 20 globally recognized biotechnology brands, Realgen-bio delivers integrated access to instruments, reagents, and consumables supporting both research and production-scale workflows.
Realgen-bio’s strength lies in its ability to connect high-performance technologies with real-world scientific applications. By providing systematic solutions across molecular biology, immunology, oncology, stem cell research, and neurobiology, the company enables researchers to move efficiently from discovery through translational and manufacturing stages.
Through this partnership, Bio X Cell strengthens its commitment to enabling reproducible, high-fidelity research in complex biological systems by expanding local access across China. Realgen-bio will provide researchers with streamlined access to Bio X Cell’s portfolio of functional antibodies, supporting a broad range of applications from in vivo studies to advanced in vitro systems, including organoid and organ-on-chip models.
Realgen-bio’s national infrastructure and technical expertise extend the reach of Bio X Cell’s globally validated antibody platform, trusted in nearly 30,000 peer-reviewed publications. These functional antibodies combine validated activity with ultrapure formulations (≥95% purity) and endotoxin levels as low as ≤0.5 EU/mg, providing the consistency and reliability required across diverse experimental workflows.
“China represents one of the most dynamic and fast-growing regions for life science and translational research,” said Christopher Conway, CEO of Bio X Cell. “Realgen-bio’s deep scientific engagement and strong customer relationships make them an ideal partner to expand access to antibodies designed for performance in living systems. This partnership ensures researchers can generate reproducible, biologically meaningful data across a wide range of applications and at every stage of their work.”
With this partnership, Bio X Cell continues to scale its global distribution network while reinforcing its role as the standard for functional antibodies, supporting researchers as they advance from mechanistic discovery to translational validation without compromising data integrity.
Researchers across China can now access Bio X Cell products directly through Realgen-bio Co., Ltd. For inquiries or to request a quote, please contact:
Jiangsu Real-gen Biotechnology Co., Ltd
Room A2-1003, No. 388 Xinping Street
Suzhou Industrial Park, China
Tel: +86 (512) 6558-5482
Email: sales@realgen-bio.com
About Bio X Cell
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.